Uniquity One (UNI)
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Uniquity One (UNI) sits in the upper quartile of US sponsors by registered trial count (#2,913 of 15,742 sponsors by registered trial count).
Uniquity One (UNI): 4 sponsored US clinical trials, 2 recruiting.
Uniquity One (UNI) sponsors 4 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting, and 1 completed. 0 of these trials are in Phase 3-4 (later-stage) and 4 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Asthma, with 1 trials.
Upper-quartile sponsor footprint
Uniquity One (UNI) sits in the upper quartile of the sponsor corpus (#2,913 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
4 total, page 1 of 1
A Study to Evaluate Solrikitug in Participants With COPD (ZION)
NCT06496620
A Study to Evaluate Solriktug in Adult Participants With Asthma
NCT06496607
A Study to Investigate the Efficacy and Safety of NSI-8226 in Adults With Eosinophilic Esophagitis
NCT06598462
A Study to Investigate Efficacy and Safety of NSI-8226 in Healthy Participants
NCT06640920
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 3 |
Therapeutic Areas
What is open in the Uniquity One (UNI) pipeline
2 recruiting of 4 indexed (50% open); 1 completed (25%).
Phase mix: 0 late (III/IV) vs 4 early (I/II) (early-phase heavy).
Top condition: Asthma (1 trial), 2 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Uniquity One (UNI): open-pipeline peers nationwide
Peers matched on 4 registered trials and 50% open enrollment, not the therapeutic-area sidebar.
Uniquity One (UNI) sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 4 trials (± recruiting share)
- 4D pharma · 4 trials · 0% recruiting
- 60 Degrees Pharmaceuticals · 4 trials · 50% recruiting
- A2 Biotherapeutics · 4 trials · 75% recruiting
- Abdul Latif Jameel Poverty Action Lab · 4 trials · 25% recruiting
Sponsors near 50% open enrollment (± trial volume)
- 1200 Pharma · 50% recruiting · 2 trials
- 1ST Biotherapeutics · 50% recruiting · 2 trials
- 3ive Labs · 50% recruiting · 2 trials
- 7 Hills Pharma · 50% recruiting · 2 trials
Related
What to do with this Uniquity One (UNI) page
4 registered trials is a research-attention snapshot, not an endorsement of Uniquity One (UNI) or any single study.
- 2 of Uniquity One (UNI)'s trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Asthma is the condition Uniquity One (UNI) studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Asthma trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Uniquity One (UNI) pipeline card: 4 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.